CONMED (CNMD) Stock Forecast & Price Target

Conmed Corp has demonstrated robust growth within key segments, particularly with the BioBrace product, which is anticipated to bolster revenues further upon its full market release in Q3 2025 following FDA approval. The company’s Foot & Ankle products have also shown strong double-digit growth, signaling recovery from previous supply constraints and enhancing overall financial resilience. Management's conservative revenue guidance reflects a strategic focus on sustained top-line improvement, which is expected to gradually enhance performance in the latter half of the year.

Conmed Corp has experienced a notable decline in its stock performance, with shares down approximately 27% year-to-date, indicating challenges in its turnaround efforts. The company's valuation has been adjusted with a price target reduction from $80 to $68, reflecting a shift to approximately 15 times the estimated FY'25 EPS of $4.46, underscoring investor caution. Additionally, capital weakness, particularly in international markets, has been observed due to difficult year-over-year comparisons, including competitor product recalls and changes in distribution, rather than a broader slowdown in hospital capital budgets.